Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing-Reference-Cited by-同舟云学术

Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing

Published:2022-02 Issue:1 Volume:54 Page:55-62
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Bourhis Amélie,Caumont Charline,Quintin-Roué Isabelle,Magro Elsa,Dissaux Gurvan,Remoué Annabelle,Le Noac’h Pierre,Douet-Guilbert Nathalie,Seizeur Romuald,Tyulyandina Alexandra,Schick Ulrike,Merlio Jean-Philippe,Marcorelles Pascale,Cappellen David,Uguen Arnaud

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference37 articles.

1. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017;Ostrom;Neuro Oncol,2020

2. A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma;Trusheim;CNS Oncol,2017

3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;Stupp;Lancet Oncol,2009

4. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma;Chinot;N Engl J Med,2014

5. A randomized trial of bevacizumab for newly diagnosed glioblastoma;Gilbert;N Engl J Med,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High prevalence of NTRK fusions in sporadic dMMR/MSI mCRC RAS/RAF wild-type: an opportunity for a post-immune checkpoint inhibitors progression rescue strategy;ESMO Gastrointestinal Oncology;2024-09

2. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors;Acta Neuropathologica Communications;2024-07-16

3. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice;Cancer Biomarkers;2023-11-20

4. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions;Modern Pathology;2023-08

5. Pan-TRK immunohistochemistry as a tool in the screening for NTRK gene fusions in cancer patients;Oncology in Clinical Practice;2023-05-29